The impact of COVID-19 on hospitalization outcomes of patients with acute myocardial infarction in the USA

Markson, F.E.; Akuna, Emmanuel; Lim, Chae Young; Khemani, L.; Amanullah, Aman

doi:10.1016/j.ahjo.2023.100305

Cited by 2 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The S protein itself is able to elevate the NLRP3 cascade in the absence of other priming signals [ 16 ]. The chronic inflammation of the patients contributes to the persistent activation of the NLRP3 inflammasome in SARS-CoV-2 infection, which may explain the relatively higher disease severity rate in patients with metabolic diseases such as type 2 diabetes [ 17 , 18 ], chronic liver disease [ 19 ], and acute myocardial infarction [ 20 ]. In contrast, patients taking immunosuppressive drugs also have weak immune surveillance activity.…”

Section: Nlrp3 Inflammasome and Sars-cov-2mentioning

confidence: 99%

Targeting Inflammasome Activation in Viral Infection: A Therapeutic Solution?

Deng,

Li,

Zhang

et al. 2023

Viruses

View full text Add to dashboard Cite

Inflammasome activation is exclusively involved in sensing activation of innate immunity and inflammatory response during viral infection. Accumulating evidence suggests that the manipulation of inflammasome assembly or its interaction with viral proteins are critical factors in viral pathogenesis. Results from pilot clinical trials show encouraging results of NLRP3 inflammasome suppression in reducing mortality and morbidity in SARS-CoV-2-infected patients. In this article, we summarize the up-to-date understanding of inflammasomes, including NLRP3, AIM2, NLRP1, NLRP6, and NLRC4 in various viral infections, with particular focus on RNA viruses such as SARS-CoV-2, HIV, IAV, and Zika virus and DNA viruses such as herpes simplex virus 1. We also discuss the current achievement of the mechanisms involved in viral infection-induced inflammatory response, host defense, and possible therapeutic solutions.

show abstract

Section: Nlrp3 Inflammasome and Sars-cov-2mentioning

confidence: 99%

Targeting Inflammasome Activation in Viral Infection: A Therapeutic Solution?

Deng,

Li,

Zhang

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

“…Among hospitalized patients with COVID-19, the mortality has been reported to be approximately 21% [ 30 ]. The frequency of COVID-19 in patients treated for STEMI reached up to 1% in epidemiological studies [ 31 , 32 ]. In our study it was 2.5%.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, Zajac et al did not observe a statistical difference in mortality. However, in that study, the observation time was limited to the procedure [ 19 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 ]. Among cited studies, only Kite et al and Markson et al assessed outcomes among patients with NSTEMI [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

The Influence of SARS-CoV-2 Infection on Acute Myocardial Infarction Outcomes

Hrycek,

Walawska-Hrycek,

Hamankiewicz

et al. 2023

JCM

View full text Add to dashboard Cite

Background: This multicenter retrospective study with a control group was designed to assess the influence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the outcomes of patients with myocardial infarction (MI). Methods: A total of 129 patients with COVID-19 who were treated for MI were included in this study. The control group comprised 129 comparable patients without SARS-CoV-2 infection. The in-hospital, out-of-hospital, and overall mortality were analyzed. Results: A total of thirty-one (24%) patients died in the study group, and two (1.6%) patients died in the control group (OR = 20.09; CI: 4.69–85.97; p < 0.001). Similar results were observed in all analyzed patient subgroups. Multivariable Cox regression analysis confirmed the significant influence of SARS-CoV-2 infection on in-hospital outcomes (HR: 8.48459; CI: 1.982–36.320; p = 0.004). Subanalysis of the groups with COVID-19 plus ST-elevation MI (STEMI) or non-ST-elevation MI (NSTEMI) revealed comparable mortality rates: 14 (21.12%) patients in the NSTEMI group and 17 (26.98%) patients in the STEMI subgroup died (OR: 1.3; CI: 0.56–3.37; p = 0.45). During out-of-hospital observation, no differences in mortality were observed (OR: 0.77; CI: 0.11–4.07; p = 0.73). Conclusions: SARS-CoV-2 infection affects the in-hospital outcomes of patients with both MI and COVID-19, regardless of MI type (STEMI vs. NSTEMI).

show abstract

The impact of COVID-19 on hospitalization outcomes of patients with acute myocardial infarction in the USA

Cited by 2 publications

References 18 publications

Targeting Inflammasome Activation in Viral Infection: A Therapeutic Solution?

Targeting Inflammasome Activation in Viral Infection: A Therapeutic Solution?

The Influence of SARS-CoV-2 Infection on Acute Myocardial Infarction Outcomes

Contact Info

Product

Resources

About